BACKGROUND: Recent research suggests that preclinical Alzheimer's disease (AD) in people with Down syndrome (DS) is characterized by changes in personality/behaviour and executive dysfunction that are more prominent than deterioration in episodic memory. This study examines the relationship between executive dysfunction and the clinical and preclinical features of AD in DS. To determine the specificity of this relationship, performance on executive function (EF) measures is contrasted with performance on memory measures. METHODS: One hundred and three people with DS (mean age 49 years, range 36-72) with mild to moderate learning disabilities (LD) took part. Dementia diagnosis was based on the CAMDEX informant interview conducted with each participant's main carer. Reported changes in personality/behaviour and memory were recorded. Participants completed six EF and six memory measures (two of which also had a strong executive component) and the BPVS (as a measure of general intellectual ability). First, performance was compared between those with and without established dementia of Alzheimer's type (DAT), controlling for age and LD severity using ANCOVA. Next, the degree to which informant-reported changes predicted cognitive test performance was examined within the non-DAT group using multiple regression analyses. RESULTS: The DAT group (N=25) showed a consistent pattern of impaired performance relative to the non-DAT group (N=78), across all measures. Within the non-DAT group, number of informant-reported personality/behaviour changes was a significant predictor of performance on two EF and two 'executive memory' tests (but not on episodic memory tests). Informant-reported memory changes, however, were associated with impaired performance on a delayed recall task only. CONCLUSIONS: These findings provide further evidence for a specific impairment in frontal-lobe functioning in the preclinical stages of AD in DS. Implications for the assessment, diagnosis, and management of dementia in DS are discussed.
BACKGROUND: Recent research suggests that preclinical Alzheimer's disease (AD) in people with Down syndrome (DS) is characterized by changes in personality/behaviour and executive dysfunction that are more prominent than deterioration in episodic memory. This study examines the relationship between executive dysfunction and the clinical and preclinical features of AD in DS. To determine the specificity of this relationship, performance on executive function (EF) measures is contrasted with performance on memory measures. METHODS: One hundred and three people with DS (mean age 49 years, range 36-72) with mild to moderate learning disabilities (LD) took part. Dementia diagnosis was based on the CAMDEX informant interview conducted with each participant's main carer. Reported changes in personality/behaviour and memory were recorded. Participants completed six EF and six memory measures (two of which also had a strong executive component) and the BPVS (as a measure of general intellectual ability). First, performance was compared between those with and without established dementia of Alzheimer's type (DAT), controlling for age and LD severity using ANCOVA. Next, the degree to which informant-reported changes predicted cognitive test performance was examined within the non-DAT group using multiple regression analyses. RESULTS: The DAT group (N=25) showed a consistent pattern of impaired performance relative to the non-DAT group (N=78), across all measures. Within the non-DAT group, number of informant-reported personality/behaviour changes was a significant predictor of performance on two EF and two 'executive memory' tests (but not on episodic memory tests). Informant-reported memory changes, however, were associated with impaired performance on a delayed recall task only. CONCLUSIONS: These findings provide further evidence for a specific impairment in frontal-lobe functioning in the preclinical stages of AD in DS. Implications for the assessment, diagnosis, and management of dementia in DS are discussed.
Authors: Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian Journal: Neurobiol Aging Date: 2017-06-02 Impact factor: 4.673
Authors: William F Sullivan; Joseph M Berg; Elspeth Bradley; Tom Cheetham; Richard Denton; John Heng; Brian Hennen; David Joyce; Maureen Kelly; Marika Korossy; Yona Lunsky; Shirley McMillan Journal: Can Fam Physician Date: 2011-05 Impact factor: 3.275
Authors: Andrea Romano; Marta Moraschi; Riccardo Cornia; Alessandro Bozzao; Maria Camilla Rossi-Espagnet; Federico Giove; Giorgio Albertini; Alberto Pierallini Journal: Neuroradiology Date: 2018-09-27 Impact factor: 2.804
Authors: Lauren T Ptomey; Amanda N Szabo; Erik A Willis; Anna M Gorczyca; J Leon Greene; Jessica C Danon; Joseph E Donnelly Journal: Disabil Health J Date: 2018-02-26 Impact factor: 2.554
Authors: David Powell; Allison Caban-Holt; Gregory Jicha; William Robertson; Roberta Davis; Brian T Gold; Frederick A Schmitt; Elizabeth Head Journal: Neurobiol Aging Date: 2014-02-04 Impact factor: 4.673
Authors: Alex M Helman; Morgan Siever; Katie L McCarty; Ira T Lott; Eric Doran; Erin L Abner; Frederick A Schmitt; Elizabeth Head Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Sigan L Hartley; Benjamin L Handen; Darlynne A Devenny; Regina Hardison; Iulia Mihaila; Julie C Price; Annie D Cohen; William E Klunk; Marsha R Mailick; Sterling C Johnson; Bradley T Christian Journal: Brain Date: 2014-07-02 Impact factor: 13.501